BioSpace News Archive

HTG Molecular Diagnostics, Inc., a life science company whose mission is to advance precision medicine, reported its financial results for the first quarter ended March 31, 2021.

Motus GI Holdings, Inc., a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, reported its financial results for the first quarter ended March 31, 2021, and provided a corporate update.

ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2021.

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of precision genetic medicines, today reported its financial results for the three- and six-month periods ended March 31, 2021.

4D Molecular Therapeutics, a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced financial results for the first quarter of 2021, and provided operational highlights.

Phase 2 trial initiation for Parkinson’s disease dementia program and IND submission for neuropsychiatric program planned by end of 2021

Topline results from a Phase 2a trial of MET409 in combination with empagliflozin in patients with NASH and type 2 diabetes now expected in the fourth quarter of 2021

TELA Bio, Inc., a commercial stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, reported financial results for the first quarter ended March 31, 2021.

Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today reported financial results for the first quarter ended March 31, 2021 and provided an update on recent business highlights.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, reported financial results for the quarter ended March 31, 2021 and provided a corporate update.